AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering

Stock Information for AIM ImmunoTech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AIM ImmunoTech Inc.

AI-Media to Showcase Real-Time Translation and Accessibility Workflows at ISE 2026 as Multilingual AV Demand Accelerates
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
AIM ImmunoTech Announces Stock Dividend
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AI-Media Launches ADA Title II Compliance Initiative to Support Public Entities Meeting WCAG 2.1 AA Deadlines
AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.